PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of $0.92, $0.60 better than the analyst estimate of $0.32. Revenue for the quarter came in at $361 million versus the consensus estimate of $293.07 million.

GUIDANCE:

PTC Therapeutics sees FY2026 revenue of $1.18-1.28 billion, versus the consensus of $1.18 billion.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.